# The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study

> **NCT06962189** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 39 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (Stage III)

## Interventions

- **DRUG:** chemoimmunothrapy

## Key facts

- **NCT ID:** NCT06962189
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962189, "The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06962189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*